University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Lloyd E. Damon, MD

Lloyd E. Damon, MD

Clinical Professor, Department of Medicine, UCSF; Director, Hematologic Malignancies and Bone Marrow Transplant, UCSF
Robert O. and Angela W. Johnson Endowed Chair in Hematopoietic Malignancies, UCSF

Cancer Center Program Memberships

Hematopoietic Malignancies

Research Summary

I have performed clinical trials in hematologic malignancies and hematopoietic cell transplantation since 1988. My focus has been predominantly in the acute leukemias and lymphomas, with emphasis on novel chemotherapy drug schedules and dosing aimed at enhancing treatment efficacy and/or reducing treatment toxicity. I discovered the relationship of high-dose cytarabine neurotoxicity and renal insufficiency that led to a dose-modification scheme that reduced neurotoxicity risk (this has become the standard of care in physicians using high doses of cytarabine). I have explored methods of adding immunotherapy to autologous hematopoietic cell transplant, most notably the GVAX platform in AML in conjunction with the Johns Hopkins group. I was the national PI on CALGB protocol 59909 adding rituximab and autologous hematopoietic cell transplant to aggressive immunochemotherapy for mantle cell lymphoma. I am the UCSF sub-PI on the Ohio State University Blood and Marrow Transplant Research Consortium within the BMT CTN. I am the campus PI on the new University of California Hematologic Malignancies Research Consortium linking UCSF, UCSD, UCD, UCLA, and UCI to facilitate clinical and collaborative scientific research in blood cancers in California.
My research activities have been tempered by additional clinical and administrative responsibilities since achieving faculty status. Based on the waxing and waning of nonmalignant hematology faculty at UCSF, I have often had to shift my clinical work to nonmalignant activities (outpatient clinic and inpatient consults) multiple times over my career. This has even included a brief term as interim director of our Hemophilia Treatment Center and participation as PI on several clinical trials in nonmalignant hematology. I am currently the director of adult hematology and blood and marrow transplantation at UCSF and the deputy chief of the division of hematology-oncology. I served on the National Comprehensive Cancer Network guideline panels for adult acute myeloid leukemia and acute lymphoblastic leukemia.

Education

Olivet College, Olivet, Michigan, B.A., 1978, Chemistry/Biology
University of Michigan Medical School, Ann Arbor, M.D., 1982, Medicine
University of California San Francisco, Residency, 1985, Internal Medicine
University of California San Francisco, Fellowship, 1988, Hematology/Oncology


Professional Experience

  • 1976-1978
    Instructor, Organic Chemistry Laboratory, Olivet College
  • 1988-1989
    Clinical Instructor of Medicine, Univ. California, San Francisco
  • 1989-1995
    Assistant Clinical Professor of Medicine, Univ. California, San Francisco
  • 1996-2000
    Associate Clinical Professor of Medicine, Univ. California, San Francisco
  • 2000-present
    Clinical Professor of Medicine, Univ. California, San Francisco
  • 1989-Present
    Director, Apheresis and Stem cell Collection Unit, University of California, San Francisco

Honors & Awards

  • 1985
    American Cancer Society Clinical Fellowship Award
  • 2001, 2003
    Faculty teaching award, Division of Hematology-Oncology
  • 2003
    Exceptional Physician Award, UCSF Medical Center
  • 2007
    "Master Clinician" Award, UCSF Department of Medicine

Selected Publications

  1. Gupta S, Damon L, Gelfand JM. Progressive Neurological Impairment and an Enhancing Brainstem Lesion in a Middle-aged Man. JAMA Neurol. 2019 Sep 16.
    View on PubMed
  2. Huang LW, Sheng Y, Andreadis C, Logan AC, Mannis GN, Smith CC, Gaensler KML, Martin TG, Damon LE, Steinman MA, Huang CY, Olin RL. Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transplant. 2019 Sep 04.
    View on PubMed
  3. Wieduwilt MJ, Pawlowska N, Thomas S, Olin R, Logan AC, Damon LE, Martin T, Kang M, Sayre PH, Boyer W, Gaensler KML, Anderson K, Munster PN, Andreadis C. Histone Deacetylase Inhibition with Panobinostat Combined with Intensive Induction Chemotherapy in Older Patients with Acute Myeloid Leukemia: Phase I Study Results. Clin Cancer Res. 2019 Aug 15; 25(16):4917-4923.
    View on PubMed
  4. Bolaños-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, Alousi AM, Antin JH, Arai S, Bickett K, Chen YB, Damon LE, Efebera YA, Geller NL, Giralt SA, Hari P, Holtan SG, Horowitz MM, Jacobsohn DA, Jones RJ, Liesveld JL, Logan BR, MacMillan ML, Mielcarek M, Noel P, Pidala J, Porter DL, Pusic I, Sobecks R, Solomon SR, Weisdorf DJ, Wu J, Pasquini MC, Koreth J. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematol. 2019 Mar; 6(3):e132-e143.
    View on PubMed
  5. Nawas MT, Andreadis C, Martin TG, Wolf JL, Ai WZ, Kaplan LD, Mannis GN, Logan AC, Damon LE, Huang CY, Olin RL. Limitation in Patient-Reported Function Is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 Jun; 25(6):1218-1224.
    View on PubMed
  6. Rahmat LT, Damon LE. The Use of Natural Health Products Especially Papaya Leaf Extract and Dandelion Root Extract in Previously Untreated Chronic Myelomonocytic Leukemia. Case Rep Hematol. 2018; 2018:7267920.
    View on PubMed
  7. Schiller GJ, Damon LE, Coutre SE, Hsu P, Bhat G, Douer D. High-Dose Vincristine Sulfate Liposome Injection, for Advanced, Relapsed, or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in an Adolescent and Young Adult Subgroup of a Phase 2 Clinical Trial. J Adolesc Young Adult Oncol. 2018 10; 7(5):546-552.
    View on PubMed
  8. Brown PA, Shah B, Fathi A, Wieduwilt M, Advani A, Aoun P, Barta SK, Boyer MW, Bryan T, Burke PW, Cassaday R, Coccia PF, Coutre SE, Damon LE, DeAngelo DJ, Frankfurt O, Greer JP, Kantarjian HM, Klisovic RB, Kupfer G, Litzow M, Liu A, Mattison R, Park J, Rubnitz J, Saad A, Uy GL, Wang ES, Gregory KM, Ogba N. NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017. J Natl Compr Canc Netw. 2017 09; 15(9):1091-1102.
    View on PubMed
  9. Mulé MP, Mannis GN, Wood BL, Radich JP, Hwang J, Ramos NR, Andreadis C, Damon L, Logan AC, Martin TG, Hourigan CS. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016 11; 22(11):1974-1982.
    View on PubMed
  10. Damon LE. The use of ibrutinib in chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 2016 Mar; 14(3):154-6.
    View on PubMed
  11. Mannis GN, Martin TG, Damon LE, Andreadis C, Olin RL, Kong KA, Faham M, Hwang J, Ai WZ, Gaensler KML, Sayre PH, Wolf JL, Logan AC. Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016 06; 22(6):1030-1036.
    View on PubMed
  12. Mannis GN, Martin TG, Damon LE, Logan AC, Olin RL, Flanders MD, Ai WZ, Gaensler KM, Kaplan LD, Sayre PH, Smith CC, Wolf JL, Andreadis C. Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission. Leuk Lymphoma. 2016 07; 57(7):1560-6.
    View on PubMed
  13. Alvarnas JC, Brown PA, Aoun P, Ballen KK, Barta SK, Borate U, Boyer MW, Burke PW, Cassaday R, Castro JE, Coccia PF, Coutre SE, Damon LE, DeAngelo DJ, Douer D, Frankfurt O, Greer JP, Johnson RA, Kantarjian HM, Klisovic RB, Kupfer G, Litzow M, Liu A, Rao AV, Shah B, Uy GL, Wang ES, Zelenetz AD, Gregory K, Smith C. Acute Lymphoblastic Leukemia, Version 2.2015. J Natl Compr Canc Netw. 2015 Oct; 13(10):1240-79.
    View on PubMed
  14. Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Erba HP, Pigneux A, Horst HA, Recher C, Klimek VM, Cortes J, Roboz GJ, Odenike O, Thomas X, Havelange V, Maertens J, Derigs HG, Heuser M, Damon L, Powell BL, Gaidano G, Carella AM, Wei A, Hogge D, Craig AR, Fox JA, Ward R, Smith JA, Acton G, Mehta C, Stuart RK, Kantarjian HM. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2015 Sep; 16(9):1025-1036.
    View on PubMed
  15. Marra J, Greene J, Hwang J, Du J, Damon L, Martin T, Venstrom JM. KIR and HLA genotypes predictive of low-affinity interactions are associated with lower relapse in autologous hematopoietic cell transplantation for acute myeloid leukemia. J Immunol. 2015 May 01; 194(9):4222-30.
    View on PubMed
  16. Stone RM, Mazzola E, Neuberg D, Allen SL, Pigneux A, Stuart RK, Wetzler M, Rizzieri D, Erba HP, Damon L, Jang JH, Tallman MS, Warzocha K, Masszi T, Sekeres MA, Egyed M, Horst HA, Selleslag D, Solomon SR, Venugopal P, Lundberg AS, Powell B. Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia. J Clin Oncol. 2015 Apr 10; 33(11):1252-7.
    View on PubMed
  17. Mannis GN, Andreadis C, Logan AC, Damon LE, Benet LZ, Ai WZ, Gaensler KM, Kaplan LD, Koplowicz YB, Linker CA, Olin RL, Sayre PH, Smith CC, Sudhindra A, Venstrom JM, Wolf JL, Martin TG. A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15(6):377-83.
    View on PubMed
  18. Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, Pigneux A, Wetzler M, Stuart RK, Erba HP, Damon LE, Powell BL, Lindeman N, Steensma DP, Wadleigh M, DeAngelo DJ, Neuberg D, Stone RM, Ebert BL. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015 Feb 26; 125(9):1367-76.
    View on PubMed
  19. Mannis GN, Logan AC, Leavitt AD, Yanada M, Hwang J, Olin RL, Damon LE, Andreadis C, Ai WZ, Gaensler KM, Greene CC, Gupta NK, Kaplan LD, Mahindra A, Miyazaki Y, Naoe T, Ohtake S, Sayre PH, Smith CC, Venstrom JM, Wolf JL, Caballero L, Emi N, Martin TG. Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis. Bone Marrow Transplant. 2015 Jan; 50(1):40-4.
    View on PubMed
  20. Keller JW, Andreadis C, Damon LE, Kaplan LD, Martin TG, Wolf JL, Ai WZ, Venstrom JM, Smith CC, Gaensler KM, Hwang J, Olin RL. Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients. J Geriatr Oncol. 2014 Jul; 5(3):238-44.
    View on PubMed

Go to UCSF Profiles, powered by CTSI